Daniel [for David Roman]'s questions to iRhythm Technologies Inc (IRTC) leadership • Q1 2025
Question
Daniel, on behalf of David Roman, asked how iRhythm views the multiparameter sensor opportunity, both for its internal pipeline and potential M&A, given the increasing number of competitors.
Answer
CEO Quentin Blackford affirmed that a multiparameter sensing platform is a key part of their 3-to-5-year strategy, building on the BioIntelliSense transaction. He expressed strong confidence in their internal innovation capabilities but noted the company is well-positioned to consider M&A for the right technology at the right valuation, provided it is a perfect strategic fit.